President Donald Trump’s bold executive order on drug pricing is not only a policy, but a revolution in healthcare affordability. The plan is simple and changeable: Ensure that Americans no longer pay for drugs than citizens of other wealthy countries.

Consider this stark reality: London's GLP-1 drugs ordered $1,000 in the United States. Even after discounts to the insurer manufacturer, Americans still pay more than $400 for the same drug from the same company that the same company produces at the same factory. This gap is especially shocking when pharmaceutical companies make 70% of their profits from the United States (a country that accounts for only 4% of the world’s population). This global free riding for American patients is now over.

Industry leaders recognize this imbalance. I've been engaged to the CEOs of four major U.S. pharmaceutical companies and a foreign manufacturer eager to relocate to the U.S., which is encouraging, but we're ready to act decisively if necessary. The Centers for Health and Public Services and Medicaid Services (CMS) have the legal powers to fulfill President Trump’s commitment: Other developed countries have to pay more, so Americans can pay less, thus retaining the innovation pipeline.

President Trump accepts "big pharma" by signing executive orders to lower drug prices

Americans deserve groundbreaking therapy and affordable therapy. However, according to the Kaiser Family Foundation, nearly one-third of patients skip prescription medications due to costs, an unacceptable reality in the world’s richest countries.

While prevention through a healthier lifestyle remains our best strategy to reduce drug dependence, certain treatments will always be essential. The pharmaceutical industry has made significant progress in cancer and autoimmune therapies that benefit patients around the world.

Click here for more Fox News comments

We regard continuous innovation as the core principle of the United States, but we cannot subsidize global medical advances indefinitely, and other wealthy countries have contributed little.

President Trump's approach to negotiation has proven effective for NATO, where European countries responded to accountability through historic reinvestment in strengthening the alliance. The same principle applies here. The President and I Stand: Global Free Riding for American Patients Must End.

Click here to get the Fox News app

CMS and Dr. Mehmet Oz are at the helm, going beyond payment reforms and fundamentally re-adjusting the nursing delivery incentives. The initiative will protect the safety nets of vulnerable populations while addressing financial pressures (especially Medicaid) faced by national partners and federal programs, which have significantly increased enrollment rates and costs.

The next few months will be the decisive decision to prescribe President Trump for a healthier United States – an innovation thrives in which patients no longer bear the unfair share of the global health care burden.

Click here to learn more about Robert F. Kennedy Jr.